Haemonetics Corporation Q1 2027 Earnings Call Summary

Moby Intelligence

Fri, August 7, 2026 at 1:46 AM GMT+3 3 min read

Haemonetics Corporation Q1 2027 Earnings Call Summary - Moby

Strategic Performance Drivers

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

Performance was characterized by broad-based execution across all three core platforms, with MedSurg reemerging as a long-term growth driver alongside durable Apheresis performance.
Plasma revenue growth of 8% was fueled by share gains and robust collection trends, successfully outrunning the prior-year divestiture and customer loss overhang.
Vascular Closure returned to double-digit growth, outperforming the market due to the stabilization of Pulsed Field Ablation (PFA) procedures and expanded label indications for VASCADE MVP XL.
The rollout of Persona PLUS is progressing ahead of schedule, delivering yield improvements exceeding 5% for early adopters and reinforcing the value of the integrated collection platform.
Hemostasis Management continues to show durable mid-teens disposable growth, driven by higher utilization and the successful global launch of the heparinase neutralization cartridge.
Operating leverage is beginning to materialize from multi-year investments in the operating model, evidenced by gross margin expansion when normalizing for prior-year software benefits.

Fiscal 2027 Outlook and Assumptions

Full-year organic revenue guidance was raised to 4% to 7%, reflecting Q1 outperformance while maintaining a balanced outlook for the remainder of the year.
Plasma guidance assumes conservative collection volume growth of 0% to 2%, despite current market trends showing high single to low-double-digit increases.
Management expects 50 to 100 basis points of adjusted operating margin expansion, supported by favorable product mix and Persona PLUS adoption despite sustained external cost pressures.
The company anticipates a $7 million tariff refund in Q2, though this is expected to be offset by headwinds from higher oil prices and material inflation later in the year.
Strategic focus for the fiscal year remains on organic growth and product launches, including the anticipated U.S. launch of PerQseal Elite and label expansion in Japan.

Operational and Risk Factors

The first quarter of fiscal 2027 is the first period reflecting the new reportable segment structure announced in June 2026.
Free cash flow conversion reached 75% of adjusted net income in a seasonally weak quarter, driven by disciplined working capital execution and fewer device placements.
Management has prioritized debt repayment, reducing the revolving credit facility balance by $100 million subsequent to the start of the fiscal year.
The addition of Dr. Martin Madaus to the Board of Directors is intended to strengthen strategic perspective and operating experience for long-term value creation.

Q&A Session Highlights

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.

Vascular Closure market share and PFA procedure impact

Management noted that PFA penetration has stabilized at 80% to 85%, which has normalized access site growth to approximately 6% to 7%.
Growth in the segment is being driven by commercial execution and the VASCADE MVP XL label expansion, which allows for broader adoption in large-bore procedures.

Persona PLUS adoption curve and revenue contribution

The rollout is a simple firmware upgrade, allowing for rapid conversion of 30 to 40 centers per week.
While the entire U.S. market could technically be converted this year, guidance only includes contracted volumes with clear implementation timelines.

Capital allocation priorities and M&A outlook

Organic growth remains the top priority, followed by debt reduction and opportunistic share repurchases under the remaining $325 million authorization.
Management explicitly stated that M&A is 'off the table for now' as the focus remains on executing against existing core product demand.